Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1614 1628
This examiner grants 42% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18002572 | ORAL LIQUID FORMULATIONS OF RUXOLITINIB | Final Rejection | Novartis AG |
| 18009128 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PHOTODERMATOSIS | Final Rejection | MITSUBISHI TANABE PHARMA CORPORATION |
| 18008750 | REJUVENATION OF AGED TISSUES BY INHIBITION OF THE PGE2 DEGRADING ENZYME, 15-PGDH | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 19243756 | PHARMACEUTICAL COMPOSITION OF ANTIPLATELET DRUG, AND USE THEREOF | Final Rejection | SHANGHAI CUREGENE PHARMACEUTICAL CO., LTD. |
| 17628794 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18006584 | USE OF 2,3,5-SUBSTITUTED THIOPHENE COMPOUND FOR PREVENTING, ALLEVIATION, OR TREATING MASTOCYTOSIS | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18041249 | BACE1 INHIBITOR TREATMENT FOR SUPPRESSING CYTOKINE STORM | Final Rejection | The Cleveland Clinic Foundation |
| 17996343 | STABLE DIGLYCERIDE EMULSIONS AND METHODS FOR TREATING ORGAN INJURY | Non-Final OA | The Trustees of Columbia University in the City of New York |
| 17231273 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | Battelle Memorial Institute |
| 17313938 | METHOD OF PERSONALIZED TREATMENT FOR CARDIOMYOPATHY AND HEART FAILURE AND OTHER RELATED DISEASES BY MEASURING RENIN ACTIVITY, PRO-RENIN, PRO-RENIN RECEPTOR LEVELS IN BLOOD | Final Rejection | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA |
| 17528050 | Methods of Treating Prostate Cancer | Non-Final OA | Janssen Pharmaceutica NV |
| 18544954 | ALKYL QUATERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES | Non-Final OA | CAAMTECH, INC. |
| 17495069 | ALKYL QUATERNARY AMMONIUM TRYPTAMINES AND THEIR THERAPEUTIC USES | Non-Final OA | CAAMTECH, INC. |
| 17794823 | NOVEL COMPOUND AND USE THEREOF | Final Rejection | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 17440895 | METHODS FOR CONTROLLING PROSTAGLANDIN-MEDIATED BIOLOGICAL PROCESSES | Non-Final OA | Cornell University |
| 18021643 | METHODS FOR TREATING REMITTING MULTIPLE SCLEROSIS | Final Rejection | BIOGEN MA INC. |
| 18621976 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) | Final Rejection | Tenax Therapeutics, Inc. |
| 17890130 | HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS | Non-Final OA | Pharmacosmos Holding A/S |
| 18025433 | METHOD FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS THROUGH CO-ADMINISTRATION OF CURCUMIN DERIVATIVE AND TGF-B RECEPTOR INHIBITOR | Final Rejection | UNIVERSITY INDUSTRY FOUNDATION, YONSEI UNIVERSITY WONJU CAMPUS |
| 18509935 | USE OF N-ACETYLCYSTEINE TO TREAT CNS DISORDERS | Non-Final OA | Burke Neurological Institute |
| 18487237 | COMBINATION FOR USE IN TREATING CANCERS | Non-Final OA | MAPKURE, LLC |
| 17856311 | ENHANCER OF PHOTODYNAMIC EFFECT IN ALA-PDT OR ALA-PDD | Final Rejection | SBI PHARMACEUTICALS CO., LTD. |
| 16478552 | COMPOSITIONS AND METHODS FOR CONTROLLING NATURAL KILLER CELL ACTIVATION AND FUNCTION | Final Rejection | BAR ILAN UNIVERSITY |
| 18041328 | PHYTONADIONE COMPOSITIONS | Non-Final OA | CIPLA LIMITED |
| 17746537 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | Final Rejection | Cereno Scientific AB |
| 18356972 | PARENTERAL TREATMENTS INVOLVING AMINOADAMANTANE DERIVATIVES | Non-Final OA | Shinkei Therapeutics, Inc. |
| 18024807 | APPLICATION OF NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND | Final Rejection | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. |
| 18034144 | APPLICATION OF BZP IN TREATMENT OF ISCHEMIC CARDIOVASCULAR AND CEREBRAL VASCULAR DISEASES | Non-Final OA | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. |
| 18134955 | METHODS OF TREATING PHELAN MCDERMID SYNDROME USING FARNESYL DIBENZODIAZEPINONES | Non-Final OA | AMO Pharma Ltd. |
| 17925173 | SOLID FORM OF MACROCYCLIC COMPOUND, PREPARATION THEREFOR AND USE THEREOF | Non-Final OA | Shenzhen TargetRx. Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy